1
|
Mhawech-Fauceglia P, McCarthy D, Tonooka A, Scambia G, Garcia Y, Dundr P, Mills AM, Moore K, Sanada S, Bradford L, Stella GC, Bookman M, Sharma SK, Selle F, Molinero L, He Y, Khor V, Landen C, Lin YG. The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study. Gynecol Oncol 2024; 186:17-25. [PMID: 38554625 DOI: 10.1016/j.ygyno.2024.03.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 03/17/2024] [Accepted: 03/21/2024] [Indexed: 04/02/2024]
Abstract
OBJECTIVE Histopathologic characteristics after neoadjuvant chemotherapy (NACT) may correlate with outcome. This study evaluates histopathologic features after immunotherapy and NACT/bevacizumab, and associated clinical outcomes. METHODS Evaluable tissue from IMagyn050/GOG3015/ENGOT-ov39 patients from prespecified anatomic sites from interval cytoreductive surgery (ICS) after NACT/bevacizumab plus atezolizumab/placebo underwent central histopathologic scoring and analyzed with clinical outcomes. RESULTS The predefined population had 243 evaluable NACT patients, with 48.1% tumors being PD-L1-positive. No statistically significant differences in PFS (16.9 months vs. 19.2 months, p = 0.21) or OS (41.5 months vs. 45.1 months, p = 0.67) between treatment arms were seen. Substantial residual tumor (RT) (3+) was identified in 26% atezolizumab vs. 24% placebo arms (p = 0.94). Most showed no (1+) necrosis (82% vs. 96%, respectively, p = 0.69), moderate (2+) to severe (3+) fibrosis (71% vs. 75%, respectively, p = 0.82), and extensive (2+) inflammation (53% vs. 47% respectively, p = 0.48). No significant histopathologic differences were identified by tissue site or by arm. Multivariate analyses showed increased risk for progression with moderate and substantial RT (13.6 mon vs. 21.1 mon, hazard ratio 2.0, p < 0.01; 13.6 mon vs. 21.1 mon, HR 1.9, p < 0.01, respectively); but decreased risk for death with extensive inflammation (46.9 mon vs. 36.3 mon, HR 0.65, p = 0.02). Inflammation also correlated with greater likelihood of response to NACT/bevacizumab plus immunotherapy (odds ratio 2.9, p < 0.01). Modeling showed inflammation as a consistent but modest predictor for OS. CONCLUSIONS Detailed histologic assessment of ICS specimens appear to identify characteristics, such as inflammation and residual tumor, that may provide insight to certain clinical outcomes. Future work potentially leveraging emerging tools may provide further insight into outcomes.
Collapse
Affiliation(s)
| | - Denis McCarthy
- Pathology Consultants (PC), Springfield, OR, United States
| | - Akiko Tonooka
- Division of Pathology at the Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Giovanni Scambia
- Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del S. Cuore, Rome, Italy
| | - Yolanda Garcia
- Parc Tauli Hospital Universitari, Institut d'Investigació I Innovació Parc Taulí (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain
| | - Pavel Dundr
- First Medical Faculty Charles University, General University Hospital in Prague, Prague, Czech Republic
| | - Anne M Mills
- University of Virginia, Charlottesville, VA, United States
| | - Kathleen Moore
- Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK, United States
| | | | | | | | | | - Sudarshan K Sharma
- University of Chicago Medicine Advent Health, Hinsdale, IL, United States
| | - Frederic Selle
- Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France
| | | | | | - Victor Khor
- Genentech, Inc., South San Francisco, CA, United States
| | - Charles Landen
- University of Virginia, Charlottesville, VA, United States
| | - Yvonne G Lin
- Genentech, Inc., South San Francisco, CA, United States.
| |
Collapse
|
2
|
Elias K, Smyczynska U, Stawiski K, Nowicka Z, Webber J, Kaplan J, Landen C, Lubinski J, Mukhopadhyay A, Chakraborty D, Connolly DC, Symecko H, Domchek SM, Garber JE, Konstantinopoulos P, Fendler W, Chowdhury D. Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles. Nat Commun 2023; 14:3350. [PMID: 37291133 PMCID: PMC10250543 DOI: 10.1038/s41467-023-38925-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Accepted: 05/19/2023] [Indexed: 06/10/2023] Open
Abstract
Identifying germline BRCA1/2 mutation carriers is vital for reducing their risk of breast and ovarian cancer. To derive a serum miRNA-based diagnostic test we used samples from 653 healthy women from six international cohorts, including 350 (53.6%) with BRCA1/2 mutations and 303 (46.4%) BRCA1/2 wild-type. All individuals were cancer-free before and at least 12 months after sampling. RNA-sequencing followed by differential expression analysis identified 19 miRNAs significantly associated with BRCA mutations, 10 of which were ultimately used for classification: hsa-miR-20b-5p, hsa-miR-19b-3p, hsa-let-7b-5p, hsa-miR-320b, hsa-miR-139-3p, hsa-miR-30d-5p, hsa-miR-17-5p, hsa-miR-182-5p, hsa-miR-421, hsa-miR-375-3p. The final logistic regression model achieved area under the receiver operating characteristic curve 0.89 (95% CI: 0.87-0.93), 93.88% sensitivity and 80.72% specificity in an independent validation cohort. Mutated gene, menopausal status or having preemptive oophorectomy did not affect classification performance. Circulating microRNAs may be used to identify BRCA1/2 mutations in patients of high risk of cancer, offering an opportunity to reduce screening costs.
Collapse
Affiliation(s)
- Kevin Elias
- Division of Gynecologic Oncology, Brigham and Women's Hospital, Boston, MA, USA
| | - Urszula Smyczynska
- Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland
| | - Konrad Stawiski
- Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland
| | - Zuzanna Nowicka
- Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland
| | - James Webber
- Division of Gynecologic Oncology, Brigham and Women's Hospital, Boston, MA, USA
| | - Jakub Kaplan
- Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Charles Landen
- Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA, USA
| | - Jan Lubinski
- International Hereditary Cancer Center of the Pomeranian Medical University, Szczecin, Poland
| | - Asima Mukhopadhyay
- Kolkata Gynecology Oncology Trials and Translational Research Group, Kolkata, West Bengal, India
| | - Dona Chakraborty
- Kolkata Gynecology Oncology Trials and Translational Research Group, Kolkata, West Bengal, India
| | | | - Heather Symecko
- Basser Center for BRCA, University of Pennsylvania, Philadelphia, PA, USA
| | - Susan M Domchek
- Basser Center for BRCA, University of Pennsylvania, Philadelphia, PA, USA
| | - Judy E Garber
- Center for BRCA and Related Genes, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Panagiotis Konstantinopoulos
- Center for BRCA and Related Genes, Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Wojciech Fendler
- Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
- Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
| | - Dipanjan Chowdhury
- Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Center for BRCA and Related Genes, Dana-Farber Cancer Institute, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
3
|
Krishnan V, Chang CW, Hamidi H, Bookman MA, Landen C, Myers T, Kajiyama H, Hietanen S, Willmott L, Thaker P, Taskiran C, Sehouli J, Khor V, Liu YL, Pignata S, Moore K, Molinero L. Abstract 5702: Ovarian cancer tumor microenvironment and atezolizumab (atezo) clinical activity: IMagyn050 sub-study. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-5702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: Tumor biomarkers such as CD8 density and location (i.e., immune inflamed phenotype) and immune rich molecular subtype have been linked to immune checkpoint blockade (ICB) overall survival (OS) in different cancers. The IMagyn050 trial (NCT03038100), which evaluated the efficacy of Atezo vs placebo (Pla) with carboplatin, paclitaxel and bevacizumab (CPB) in front line ovarian cancer patient (pts), did not meet its co-primary endpoints of PFS in ITT or PD-L1+ (Moore et al. JCO 2021). In the current IMagyn050 substudy we assessed potential predictive tumor immune biomarkers for Atezo clinical benefit.
Methods: FFPE tumors from the biomarker evaluable population were tested for PD-L1 IHC, CD8/PanCK IHC (total CD8 T cells and immune location phenotypes [inflamed, excluded, desert]) and RNA-seq (to derive molecular subtypes, biological pathways and cellular components [xCELL]) in tissue from baseline (n=860), on-treatment (OT, 9 weeks, n=233), intra- (n=8) and inter-lesion (n=12) matched samples. Hazard ratio (HR) interaction test from multivariate adjusted Cox-regression analysis for PFS and OS was performed to test predictive biomarkers.
Results: While tumors with CD8 T cells, immunoreactive molecular subtypes or immune inflamed phenotype were enriched for PD-L1+, only pts with immune inflamed tumors showed improved OS Atezo benefit (HR 0.67). Improved Atezo PFS/OS benefit was also observed in pts with whose tumors had high oxidative phosphorylation (OXPHOS, HR: 0.72/0.65) and UV Response (UV, HR: 0.64/0.58) but not IFNγ response. Plasma B cells were linked to improved OS Atezo benefit vs Pla (HR 0.53). We leveraged OT samples from pts in the neoadjuvant cohort to assess treatment effect on the tumor microenvironment. Analyses showed that CPB reduced tumor proliferation and increased tumor immune inflammation (CD8 T cells, PD-L1 and IFNα/IFNγ response), further increased by Atezo. Immune inflammation is challenging in ovarian cancer due to extensive tumor heterogeneity. Prevalence of tumor biomarkers varied by anatomic locations: total CD8, CD8 localization and molecular subtypes. Inter- and intra-lesion biomarker status within the same pt showed PD-L1 and plasma B cells as most consistent. Molecular subtypes and immune phenotypes had moderate intra-lesion agreement but discordant between lesions. PD-L1 and OXPHOS were the only biomarkers linked to Atezo benefit regardless of anatomical location.
Conclusion: This comprehensive exploratory study suggests that DNA damage, OXPHOS, plasma B cells and immune inflamed tumors, but not molecular subtypes or total CD8 T cells, may predict Atezo + CPB OS. This treatment promotes immune inflammation in OC tumors. Notably, we found that several biomarkers are highly heterogeneous. Our findings highlight the challenges of achieving durable clinical benefit from targeted immunotherapy in ovarian cancer pts.
Citation Format: Venkatesh Krishnan, Ching-Wei Chang, Habib Hamidi, Michael A. Bookman, Charles Landen, Tashanna Myers, Hiroaki Kajiyama, Sakari Hietanen, Lyndsay Willmott, Premal Thaker, Cagatay Taskiran, Jalid Sehouli, Victor Khor, Yvonne Lin Liu, Sandro Pignata, Kathleen Moore, Luciana Molinero. Ovarian cancer tumor microenvironment and atezolizumab (atezo) clinical activity: IMagyn050 sub-study. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5702.
Collapse
Affiliation(s)
- Venkatesh Krishnan
- 1Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA
| | - Ching-Wei Chang
- 2Personalized Healthcare and Early Development Oncology Biostatistics, Genentech, Inc., South San Francisco, CA
| | - Habib Hamidi
- 1Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA
| | - Michael A. Bookman
- 3Gynecologic Oncology Group Foundation (GOG-F) and Kaiser Permanente Northern California, San Francisco, CA
| | - Charles Landen
- 4Gynecologic Oncology Group Foundation (GOG-F) and University of Virginia, Charlottesville, VA
| | - Tashanna Myers
- 5Gynecologic Oncology Group Foundation (GOG-F) and Baystate Medical Center, Springfield, MA
| | | | | | | | - Premal Thaker
- 9Gynecologic Oncology Group Foundation (GOG-F) and Washington University School of Medicine, St Louis, MO
| | - Cagatay Taskiran
- 10Turkish Society of Gynecologic Oncology (TRSGO) and Koc University School of Medicine and VKV American Hospital, Istanbul, Turkey
| | - Jalid Sehouli
- 11Arbeitsgemeinschaft Gynaekologische Onkologie (AGO)/Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (North-Eastern German Society of Gynaecologic Oncology; NOGGO) and Charité-Medical University of Berlin (Campus Virchow Klinikum), Berlin, Germany
| | - Victor Khor
- 12Product Development Oncology, Genentech, Inc., South San Francisco, CA
| | - Yvonne Lin Liu
- 12Product Development Oncology, Genentech, Inc., South San Francisco, CA
| | - Sandro Pignata
- 13Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) and Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy
| | - Kathleen Moore
- 14Gynecologic Oncology Group Foundation (GOG-F) and Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK and Sarah Cannon Research Institute, Nashville, TN
| | - Luciana Molinero
- 1Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA
| |
Collapse
|
4
|
Landen C, Molinero L, Sehouli J, Miller A, Moore K, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker P, Blank S, Khor V, Wu F, Lin Y, Pignata S. Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: exploratory analyses of IMagyn050/GOG3015/ENGOT-ov39. Gynecol Oncol 2021. [DOI: 10.1016/s0090-8258(21)00716-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Chefetz I, Grimley E, Yang K, Hong L, Vinogradova EV, Suciu R, Kovalenko I, Karnak D, Morgan CA, Chtcherbinine M, Buchman C, Huddle B, Barraza S, Morgan M, Bernstein KA, Yoon E, Lombard DB, Bild A, Mehta G, Romero I, Chiang CY, Landen C, Cravatt B, Hurley TD, Larsen SD, Buckanovich RJ. A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells. Cell Rep 2019; 26:3061-3075.e6. [PMID: 30865894 PMCID: PMC7061440 DOI: 10.1016/j.celrep.2019.02.032] [Citation(s) in RCA: 91] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2018] [Revised: 01/19/2019] [Accepted: 02/07/2019] [Indexed: 12/15/2022] Open
Abstract
Ovarian cancer is typified by the development of chemotherapy resistance. Chemotherapy resistance is associated with high aldehyde dehydrogenase (ALDH) enzymatic activity, increased cancer "stemness," and expression of the stem cell marker CD133. As such, ALDH activity has been proposed as a therapeutic target. Although it remains controversial which of the 19 ALDH family members drive chemotherapy resistance, ALDH1A family members have been primarily linked with chemotherapy resistant and stemness. We identified two ALDH1A family selective inhibitors (ALDH1Ai). ALDH1Ai preferentially kills CD133+ ovarian cancer stem-like cells (CSCs). ALDH1Ai induce necroptotic CSC death, mediated, in part, by the induction of mitochondrial uncoupling proteins and reduction in oxidative phosphorylation. ALDH1Ai is highly synergistic with chemotherapy, reducing tumor initiation capacity and increasing tumor eradication in vivo. These studies link ALDH1A with necroptosis and confirm the family as a critical therapeutic target to overcome chemotherapy resistance and improve patient outcomes.
Collapse
Affiliation(s)
- Ilana Chefetz
- Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
| | - Edward Grimley
- Division of Hematology-Oncology, Department of Internal Medicine, Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA
| | - Kun Yang
- Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
| | - Linda Hong
- Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA
| | | | - Radu Suciu
- Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA
| | - Ilya Kovalenko
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA
| | - David Karnak
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
| | - Cynthia A Morgan
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Mikhail Chtcherbinine
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Cameron Buchman
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Brandt Huddle
- Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA
| | - Scott Barraza
- Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA
| | - Meredith Morgan
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
| | - Kara A Bernstein
- Department of Microbiology and Molecular Genetics, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA, USA
| | - Euisik Yoon
- Department of Electrical Engineering and Computer Science, University of Michigan, Ann Arbor, MI, USA
| | - David B Lombard
- Department of Pathology and Institute of Gerontology, University of Michigan, Ann Arbor, MI, USA
| | - Andrea Bild
- Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA
| | - Geeta Mehta
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA
| | - Iris Romero
- Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA
| | - Chun-Yi Chiang
- Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA
| | - Charles Landen
- Department of Obstetrics and Gynecology, School of Medicine, University of Virginia, Charlottesville, VA, USA
| | - Benjamin Cravatt
- Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA
| | - Thomas D Hurley
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Scott D Larsen
- Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA
| | - Ronald J Buckanovich
- Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA; Division of Hematology-Oncology, Department of Internal Medicine, Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA; Magee-Womens Research Institute, Pittsburgh, PA, USA.
| |
Collapse
|
6
|
|
7
|
Abstract
Full thickness colonic prolapse following pseudocontinent perineal colostomy has not been previously reported. Possible contributing factors include a large skin aperture at the site of the perineal stoma, the absence of anal sphincters and mesorectal attachments and the presence of a perineal hernia. A novel application of sacral pexy combined with perineal hernia repair using two prosthetic meshes is described.
Collapse
Affiliation(s)
- S Landen
- Department of Surgery, Clinique Edith Cavell , Brussels , Belgium.,Cliniques Universitaires St Luc , Brussels , Belgium
| | - D Ursaru
- Department of Surgery, Clinique Edith Cavell , Brussels , Belgium
| | - V Delugeau
- Department of Medicine, Groupe Hospitalier Epsylon , Brussels , Belgium
| | - C Landen
- Louvain University Medical School , Brussels , Belgium
| |
Collapse
|
8
|
Abstract
BACKGROUND Operative injury to the hepatic artery is a serious complication of pancreaticoduodenectomy and guidelines to manage this complication are lacking. METHODS A systematic search performed in PubMed database identified eleven studies overall including 20 patients having sustained injury to the hepatic artery during pancreaticoduodenectomy (n=18) or total pancreatectomy (n=2). One further unpublished personal observation following pancreaticoduodenectomy was also included. RESULTS Sixteen of 21 patients (76%) experienced serious complications including liver necrosis/abscess (n=14), acute liver failure (n=3), and biliary anastomotic dehiscence (n=6). Eleven patients (52%) were reoperated and 5 patients died (24%). Arterial injury was recognized and repaired immediately in five patients, four recovering uneventfully and one dying from acute liver failure (20%). In contrast delayed or conservative treatment in 16 patients was associated with serious early morbidity in 15 patients (94%), leading to death in 4 patients and late biliary complications in four others. CONCLUSIONS Accidental interruption of arterial flow to the liver during pancreaticoduodenectomy often results in serious short and long-term consequences. Immediate restoration of arterial flow is indicated whenever technically feasible and may prevent early life-threatening complications as well as late biliary stenosis.
Collapse
Affiliation(s)
- S Landen
- Department of surgery, CHIREC hospitals, 32, rue Edith-Cavell, 1180 Brussels, Belgium.
| | - D Ursaru
- Department of surgery, CHIREC hospitals, 32, rue Edith-Cavell, 1180 Brussels, Belgium
| | - V Delugeau
- Department of medicine, groupe hospitalier Epsylon, 34, avenue Boetendael, 1180 Brussels, Belgium
| | - C Landen
- Louvain university medical school, avenue Mounier, 1200 Brussels, Belgium
| |
Collapse
|
9
|
Arend RC, Gangrade A, Haygood CLW, Kurpad C, Metge BJ, Samant RS, Li PK, Li Y, Bhasin D, Landen C, Alvarez R, Straughn JM, Buchsbaum DJ. Abstract POSTER-THER-1402: Overcoming platinum resistance in ovarian cancer with niclosamide. Clin Cancer Res 2015. [DOI: 10.1158/1557-3265.ovcasymp14-poster-ther-1402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objective: Niclosamide, a salicyclamide derivative and FDA approved teniacide, exhibits potent effects against ovarian cancer in vitro by inhibiting the Wnt/β-catenin, STAT3, and mTOR pathways. Unfortunately, its low bioavailability as a chemotherapeutic agent in vivo necessitates investigation of analogs with improved pharmacokinetics and pharmacodynamics. The objective of this study was to investigate the role of targeting the Wnt/β-catenin and STAT3 pathways with niclosamide and niclosamide analogs (C-11 and C-32) in platinum-sensitive and -resistant ovarian cancer cell lines, primary ovarian cancer ascites cell populations, and tumor tissues. In addition, carboplatin and/or LLL12, a novel STAT3 inhibitor effective against ovarian cancer, were used in combination with niclosamide and its analogs to test for synergistic cytotoxicity. Methods: Two ovarian cancer cell lines A2780, SKOV3ip1 and their chemo-resistant derivatives, A2780.cp20 and SKOV3ip2.TRip2, were treated with niclosamide or C-11 or C-32 (0.1 to 5 μM) alone or in combination with carboplatin (5 to 150 μM) or LLL12 (0.1 nM - 10 µM). Tumorspheres were isolated from the ascites of ovarian cancer patients who underwent surgery. Tumor slices were prepared from freshly obtained ovarian cancer specimens. ATPLite assay was performed to measure cytotoxicity in cell lines, tumorspheres, and tumor slices. Western blot was used to assess expression of proteins implicated in the Wnt, mTOR, and STAT3 pathways. β-catenin signaling activity was measured using the TOPflash reporter assay. Results: All four cell lines were sensitive to niclosamide, C-11, and C-32 with similar IC50 values. Additive cytotoxicity was seen when niclosamide or its analogs were combined with carboplatin or LLL12 in the cell lines, tumorspheres, and tumor tissues. Ex vivo and in vitro samples from the same patient demonstrated similar cytotoxicity with niclosamide, C-11, and C-32 treatment. Synergism was also seen between carboplatin and LLL12 in vitro. The TOPflash assay showed that the combination of niclosamide (0.4 μM) and LLL12 (0.25 μM) decreased β-catenin activity more than either agent alone, suggesting that there is crosstalk between the STAT3 and Wnt/β-catenin pathways. Wnt/β-catenin, STAT3, and mTOR pathway target proteins (LRP6, pLRP6, Axin2, and Survivin) were downregulated with niclosamide and C-32 treatment, and to a greater degree with C-11. Conclusion: Combination treatment with niclosamide, or its analogs, with carboplatin or LLL12 induced greater cytotoxicity than either agent alone in ovarian cancer cell lines, primary tumorspheres, and tumor slices. The synergistic cytotoxicity seen in platinum-resistant cell lines with niclosamide, or its analogs, in combination with carboplatin suggest that targeting the Wnt/ β-catenin and STAT3 pathways may prove effective in overcoming chemoresistance in patients with platinum resistant ovarian cancer.
Citation Format: Rebecca C. Arend, MD, Abhishek Gangrade, Christen L. Walters Haygood, MD, Chandrika Kurpad, Brandon J. Metge, Rajeev S. Samant, PhD, Pui-Kai Li, PhD, Yonghe Li, PhD, Deepak Bhasin, PhD, Charles Landen, MD, Ronald Alvarez, MD, J. Michael Straughn, MD, Donald J. Buchsbaum, PhD. Overcoming platinum resistance in ovarian cancer with niclosamide [abstract]. In: Proceedings of the 10th Biennial Ovarian Cancer Research Symposium; Sep 8-9, 2014; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(16 Suppl):Abstract nr POSTER-THER-1402.
Collapse
Affiliation(s)
| | | | | | | | - Brandon J. Metge
- 3Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama,
| | - Rajeev S. Samant
- 3Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama,
| | - Pui-Kai Li
- 4Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, Columbus, Ohio,
| | - Yonghe Li
- 5Southern Research Institute, Birmingham, Alabama
| | - Deepak Bhasin
- 4Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, Columbus, Ohio,
| | | | | | | | | |
Collapse
|
10
|
Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, Chinemerem U, Gates C, Reddy A, Danner O, Franklin G, Ngozi A, Cantuaria G, Singh K, Grizzle W, Landen C, Partridge EE, Rice VM, Reddy ESP, Rao VN. Epithelial ovarian cancer: An overview. World J Transl Med 2014; 3:1-8. [PMID: 25525571 PMCID: PMC4267287 DOI: 10.5528/wjtm.v3.i1.1] [Citation(s) in RCA: 96] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Revised: 01/16/2014] [Accepted: 03/04/2014] [Indexed: 02/05/2023] Open
Abstract
Ovarian cancer is the second most common gynecological cancer and the leading cause of death in the United States. In this article we review the diagnosis and current management of epithelial ovarian cancer which accounts for over 95 percent of the ovarian malignancies. We will present various theories about the potential origin of ovarian malignancies. We will discuss the genetic anomalies and syndromes that may cause ovarian cancers with emphasis on Breast cancer type 1/2 mutations. The pathology and pathogenesis of ovarian carcinoma will also be presented. Lastly, we provide a comprehensive overview of treatment strategies and staging of ovarian cancer, conclusions and future directions.
Collapse
|
11
|
Chien J, Kuang R, Landen C, Shridhar V. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol 2013; 3:251. [PMID: 24069583 PMCID: PMC3781360 DOI: 10.3389/fonc.2013.00251] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2013] [Accepted: 09/09/2013] [Indexed: 01/06/2023] Open
Abstract
Despite several advances in the understanding of ovarian cancer pathobiology, in terms of driver genetic alterations in high-grade serous cancer, histologic heterogeneity of epithelial ovarian cancer, cell-of-origin for ovarian cancer, the survival rate from ovarian cancer is disappointingly low when compared to that of breast or prostate cancer. One of the factors contributing to the poor survival rate from ovarian cancer is the development of chemotherapy resistance following several rounds of chemotherapy. Although unicellular drug resistance mechanisms contribute to chemotherapy resistance, tumor microenvironment and the extracellular matrix (ECM), in particular, is emerging as a significant determinant of a tumor’s response to chemotherapy. In this review, we discuss the potential role of the tumor microenvironment in ovarian cancer recurrence and resistance to chemotherapy. Finally, we propose an alternative view of platinum-sensitive recurrence to describe a potential role of the ECM in the process.
Collapse
Affiliation(s)
- Jeremy Chien
- Department of Cancer Biology, University of Kansas Medical Center , Kansas City, KS , USA
| | | | | | | |
Collapse
|
12
|
Shah M, Nowsheen S, Katre A, Dobbin Z, Erickson B, Alvarez R, Konstantinopoulos P, Yang E, Landen C. Towards personalized PARP therapy: XRT-induced Rad51 predicts re- sponse to ABT-888 in ovarian cancer. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Walters C, Straughn J, Landen C, Estes J, Huh W, Kim K. Port-site metastases after robotic surgery for gynecologic malignancy. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Qin Y, Xu J, Aysola K, Oprea G, Reddy A, Matthews R, Okoli J, Cantor A, Grizzle WE, Partridge EE, Reddy ESP, Landen C, Rao VN. BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9. Am J Cancer Res 2012; 2:540-8. [PMID: 22957306 PMCID: PMC3433105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2012] [Accepted: 08/05/2012] [Indexed: 06/01/2023] Open
Abstract
Mutation in the BRCA1 gene is associated with increased risk for hereditary breast and ovarian cancers. In sporadic ovarian tumors, BRCA1 dysfunction is thought to be common. BRCA1 is a nuclear-cytoplasm shuttling protein. Our group has previously reported that BRCA1 proteins, unlike K109R and cancer-predisposing mutant C61G BRCA1 proteins, bind the sole SUMO E2-conjugating enzyme Ubc9. In this study, we examined the result of altered Ubc9 binding and knockdown on the sub-cellular localization and growth inhibitory function of BRCA1 proteins in ovarian cancer cells. Using live imaging of YFP, RFP-tagged BRCA1 and BRCA1a proteins, our results show enhanced cytoplasmic localization of K109R and C61G mutant BRCA1 proteins in ES-2, NIHOVCAR3 and UWB 1.289 ovarian cancer cells. Down-regulation of Ubc9 in ovarian cancer cells using Ubc9 siRNA resulted in cytoplasmic localization of BRCA1 and BRCA1a proteins. These mutant BRCA1a proteins were impaired in their capacity to inhibit growth of ES-2 ovarian cancer cells. Several ovarian cancer cells, including a BRCA1-null ovarian cancer cell line, showed higher levels of expression of Ubc9. This is the first study demonstrating the physiological link between loss of Ubc9 binding and loss of growth suppression of disease-associated mutant BRCA1a proteins in ovarian cancer cells. BRCA1, by turning off or on Ubc9 binding, regulates growth of ovarian cancers.
Collapse
Affiliation(s)
- Yunlong Qin
- Cancer Biology Program, Department of OB/GYN, Georgia Cancer Center for Excellence, Grady Health SystemAtlanta, GA 30303, USA
| | - Jingyao Xu
- Cancer Biology Program, Department of OB/GYN, Georgia Cancer Center for Excellence, Grady Health SystemAtlanta, GA 30303, USA
| | - Kartik Aysola
- Cancer Biology Program, Department of OB/GYN, Georgia Cancer Center for Excellence, Grady Health SystemAtlanta, GA 30303, USA
| | | | - Avinash Reddy
- Cancer Biology Program, Department of OB/GYN, Georgia Cancer Center for Excellence, Grady Health SystemAtlanta, GA 30303, USA
| | - Roland Matthews
- Cancer Biology Program, Department of OB/GYN, Georgia Cancer Center for Excellence, Grady Health SystemAtlanta, GA 30303, USA
| | - Joel Okoli
- Department of Surgery Morehouse School of Medicine, Georgia Cancer Center for Excellence, Grady Health SystemAtlanta, GA 30303, USA
| | - Alan Cantor
- Department of Pathology, University of Alabama at Birmingham703 19 Street South, Birmingham, AL 35294-0007, USA
| | - William E Grizzle
- Department of Pathology, University of Alabama at Birmingham703 19 Street South, Birmingham, AL 35294-0007, USA
| | - Edward E Partridge
- Department of Obstetrics & Gynecology, Division of Gynecological Oncology, 618 20 Street South, University of Alabama at BirminghamBirmingham AL 35233-7333, USA
| | - E Shyam P Reddy
- Cancer Biology Program, Department of OB/GYN, Georgia Cancer Center for Excellence, Grady Health SystemAtlanta, GA 30303, USA
| | - Charles Landen
- Department of Obstetrics & Gynecology, Division of Gynecological Oncology, 618 20 Street South, University of Alabama at BirminghamBirmingham AL 35233-7333, USA
| | - Veena N Rao
- Cancer Biology Program, Department of OB/GYN, Georgia Cancer Center for Excellence, Grady Health SystemAtlanta, GA 30303, USA
| |
Collapse
|
15
|
Ziebarth A, Dobbin Z, Katre A, Steg A, Alvarez R, Conner M, Landen C. Primary ovarian cancer murine xenografts maintain tumor heterogeneity and biologically correlate with patient response to primary chemotherapy. Gynecol Oncol 2012. [DOI: 10.1016/j.ygyno.2011.12.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
16
|
Yang E, Nowsheen S, Cooper T, Landen C, Bonner J. Poly (ADP-Ribose) polymerase inhibition attenuates radiation-induced non-homologous end-joining repair and augments cervical cancer response to radiation. Gynecol Oncol 2012. [DOI: 10.1016/j.ygyno.2011.12.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Bradley AT, Zheng H, Ziebarth A, Sakati W, Eier S, Lopez-Berestein G, Sood AK, Landen C, Eblen ST. Abstract 1649: The E3 ubiquitin ligase EDD regulates platinum resistance and is a novel therapeutic target for epithelial ovarian cancer. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-1649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Ovarian cancer is treated with a combination of surgery and chemotherapeutics, including taxol and platinum agents. A major difficulty in eradicating these tumors is the selection of drug resistant cells. EDD (E3-ubiquitin ligase identified by Differential Display) is a 300 kDa E3 ubiquitin ligase that is overexpressed in 84% of recurrent, platinum-resistant ovarian cancers, but is rare in benign in borderline tumors. This correlation with chemoresistance suggests that EDD may be involved in mediating platinum resistance and/or tumor survival.
Experimental Procedures: EDD protein knockdown was accomplished using siRNA (small interfering RNA) and shRNA (short hairpin RNA) for transient or stable knockdown, respectively, in ovarian cancer cell lines. Apoptosis and sensitivity to cisplatin were measured using MTS assay, propidium iodide staining, and western blotting for PARP and caspase 3 cleavage. Cisplatin resistance by EDD overexpression was determined by transient transfection of GFP, FLAG-EDD or the ubiquitin ligase deficient FLAG-EDD-C2768A into COS-7 cells followed by cisplatin treatment and apoptosis measurement in transfected cells by the TACS 2 TdT-Blue Label Kit followed by microscopy. Mice with intraperitoneal xenografts of ES2 and A2780ip2 cells were treated once weekly with cisplatin and twice weekly with control or EDD siRNA.
Results: EDD was overexpressed in 5 of 7 ovarian cancer cell lines compared to benign IOSE cells. EDD overexpression in COS-7 cells was sufficient to protect from cisplatin-induced apoptosis and the induced resistance was dependent upon EDD ubiquitin ligase activity (relative apoptosis: GFP = 1; EDD = 0.42, EDD-C2768A = 1.23). Stable knockdown of EDD increased cisplatin sensitivity in ES2 cells (IC50 = 37 μM for control, 9 μM for EDD shRNA). EDD siRNA alone induced cleavage of PARP and caspase 3 compared to control siRNA and enhanced cleavage of both in the presence of cisplatin. Mouse xenograft studies demonstrated that nanoliposomal delivery (DOPC) of EDD siRNA showed a trend towards reduced tumor compared to control siRNA. In vivo, mice treated with EDD siRNA by nanoliposomal delivery (DOPC) had a trend towards less tumor than those treated with control siRNA (27.7% reduction in ES2, 42.5% in A2780ip2, p = 0.23 and 0.19 respectively). Mice treated with combined EDD siRNA and cisplatin had significantly less tumor than controls (77.9% reduction in ES2, 75.9% in A2780ip2, p = 0.004 and 0.042, respectively) and cisplatin alone (60.3-64.4% reduction, p = 0.035).
Conclusions: EDD overexpression is sufficient to promote cisplatin resistance, dependent upon its E3 ubiquitin ligase activity. Targeting EDD expression induces apoptosis and cisplatin. sensitivity in vitro and in vivo. Targeting EDD may be an effective treatment for platinum-resistant ovarian cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1649. doi:10.1158/1538-7445.AM2011-1649
Collapse
Affiliation(s)
| | - Hui Zheng
- 1Medical University of South Carolina, Charleston, SC
| | | | - Wayne Sakati
- 1Medical University of South Carolina, Charleston, SC
| | - Sande Eier
- 1Medical University of South Carolina, Charleston, SC
| | | | - Anil K. Sood
- 3University of Texas MD Anderson Center, Houston, TX
| | | | | |
Collapse
|
18
|
Zsebik G, Kim K, Straughn J, Landen C. Management of complex pelvic masses using the OVA1 test: A decision analysis. Gynecol Oncol 2011. [DOI: 10.1016/j.ygyno.2010.12.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Ziebarth A, Zheng H, Bradley A, Sakati W, Eier S, Lopez-Berestein G, Sood A, Eblen S, Landen C. The ubiquitin ligase EDD mediates platinum resistance and is a target for therapy in epithelial ovarian cancer. Gynecol Oncol 2011. [DOI: 10.1016/j.ygyno.2010.12.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
20
|
Imai M, Landen C, Ohta R, Cheung NKV, Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 2006; 65:10562-8. [PMID: 16288049 DOI: 10.1158/0008-5472.can-05-1894] [Citation(s) in RCA: 108] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The role of complement in antibody therapy of cancer is in general poorly understood. We used the EL4 syngeneic mouse model of metastatic lymphoma to investigate the role of complement in immunotherapy directed against GD2, a target of clinical relevance. IgG2a and IgM anti-GD2 therapy protected EL4-challenged mice from metastases and prolonged survival. Expression of CD59, an inhibitor of direct complement-mediated cytotoxicity (CMC), effectively protected EL4 cells from CMC in vitro but did not affect the outcome of monoclonal antibody therapy. Protection by IgG therapy was also unaffected in mice deficient in C3 or complement receptor 3 (CR3) but was almost completely abrogated in FcgammaR I/III-deficient mice. These data indicate a crucial role for antibody-dependent cell-mediated cytoxicity (ADCC). However, at lower doses of IgG, therapeutic effect was partially abrogated in C3-deficient mice, indicating complement-mediated enhancement of ADCC at limiting IgG concentration. In contrast to IgG, the therapeutic effect of IgM was completely abrogated in C3-deficient mice. High level expression of CD59 on EL4 did not influence IgM therapy, suggesting IgM functions by complement-dependent cell-mediated cytotoxicity (CDCC), a mechanism thought to be inactive against tumor cells. Thus, IgG and IgM can operate via different primary mechanisms of action, and CDCC and complement-dependent enhancement of ADCC mechanisms are operative in vivo. The effects of complement can be supplemental to other antibody-mediated mechanisms and likely have increased significance at limiting antibody concentration or low antigen density.
Collapse
Affiliation(s)
- Masaki Imai
- Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina 29424, USA
| | | | | | | | | |
Collapse
|
21
|
|